Drug extends survival, reverses some neuromuscular damage in animals
About 20,000 people in the United States are living with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The invariably fatal disease kills the nerve cells that control walking, eating and breathing. Few people survive more than three years after diagnosis.
Now, new research led by Washington University School of Medicine in St. Louis indicates an investigational therapy for an inherited form of ALS extends survival and reverses signs of neuromuscular damage in mice and rats. The findings, published July 16 in The Journal of Clinical Investigation, have led to a phase one/two clinical trial to investigate whether the drug could benefit people with ALS whose disease is caused by mutations in a gene called SOD1.
“This drug had an impressive effect in mice and rats with just one or two doses,” said Timothy Miller, MD, PhD, the David Clayson Professor of Neurology at Washington University. “We don’t know yet if this works in people, but we’re very hopeful. We’ve completed the first phase of safety testing, and now we’re working on finding the right dose.”
About 10 percent of ALS cases are inherited. Of those, about a fifth are caused by mutations in SOD1. Such mutations cause the SOD1 protein to be overly active, which suggests that reducing protein levels might help ALS patients with SOD1 mutations.
Patients with ALS have few options for treatment. Only two drugs have been approved by the Food and Drug Administration (FDA) for ALS, and both only modestly slow the course of the disease.
In collaboration with Ionis Pharmaceuticals, Miller and colleagues tested DNA-based compounds that block the body from making SOD1 protein.
Miller and colleagues at Ionis tested two such compounds – known as antisense oligonucleotides, or oligos for short – in mice and rats. The animals were genetically modified to carry a mutated form of the human SOD1 gene. By a few months old, such animals start having trouble walking and feeding themselves.
Mice were given an anti-SOD1 oligo or a placebo at day 50, and a second dose about six weeks later. The mice that received the active drug maintained their weight 26 days longer and lived 37 days longer than those given the placebo, an increase in life span of 22 percent.
As a comparison, the researchers also tested the treatment in rats. The rats that received an active oligo fared much better than the ones that received the placebo. They maintained their weight more than nine weeks longer and survived eight to nine weeks longer.
The oligos also reversed signs of neuromuscular damage in the animals. By nine weeks old, mice that carry the mutant SOD1 gene are already showing molecular signs of deteriorating neuromuscular function. To find out whether the drug could reverse this decline, researchers treated 9-week-old mice with an anti-SOD1 oligo or a placebo. Muscle function steadily improved over the next eight weeks in the mice that received the active drug, while it continued to decline in the placebo group. A sign of neurological damage rose in both groups, but it rose more than twice as quickly in the mice that received the placebo than the ones given the active oligo.
Miller’s colleague at the School of Medicine, Robert Bucelli, MD, PhD, an associate professor of neurology, leads a phase one/two clinical trial based on Miller’s research. The trial is designed to evaluate the safety of using the oligos in people. Initial safety testing did not identify any obvious hazards. Now, they are testing different doses and regimens to find the most effective way to reduce SOD1 levels without causing unacceptable side effects.
“The phase one/two trial is really still a safety trial,” Miller said. “There are not enough patients in it to really be able to accurately see an effect on disease. But we’re on the cusp of testing the hypothesis that people with ALS caused by mutations in SOD1 can benefit from this treatment. We predict the effect will be good, but we can’t know until we test it.”
Learn more: New ALS therapy in clinical trials
Receive an email update when we add a new ALS article.
The Latest on: ALS therapy
via Google News
The Latest on: ALS therapy
- VTCRI scientists find that sensory neurons can be used to discover therapies for ALS on November 8, 2018 at 7:52 am
Other authors on the study include Natalia Sutherland, a first-year student in the Virginia Tech Carilion School of Medicine, Sihui Zhang, formerly a postdoctoral associate in the Valdez lab, and two ... […]
- People living with ALS share their data in extraordinary effort to end the devastating disease on November 8, 2018 at 6:20 am
“We are building a knowledge base so strong that the global ALS research community will be able to harness the power of artificial intelligence to ultimately predict a patient’s disease course and opt... […]
- Gene therapy injection into spinal cord halts ALS in adult mice on November 6, 2018 at 6:36 am
A new delivery method could take us a step closer to a gene therapy for amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder in which nerve cells progressively stop working throughout the ... […]
- Novartis says $4m price is reasonable for SMA gene therapy on November 6, 2018 at 12:37 am
Novartis’ therapy is a one-time treatment to restore ... candidates for Rett syndrome and amyotrophic lateral sclerosis (ALS) in preclinical development. Don't miss your daily pharmaphorum ... […]
- Realizing the potential of gene therapy for neurological disorders on November 5, 2018 at 8:24 pm
Scientists have successfully used gene therapy to slow the progression and improve symptoms of disorders such as amyotrophic lateral sclerosis and Parkinson's disease. Promising findings from preclini... […]
- How Stem Cell Therapy can play a vital role in treatment of infertility on November 3, 2018 at 1:08 pm
Stem Cell Therapy has emerged as very promising biomedical technique ... spinal cord injuries, motor neuronal disease (ALS), auto-immune diseases, Crohn’s disease, rheumatoid arthritis, diabetes and e... […]
- UMass Medical researchers near ALS breakthrough on November 3, 2018 at 10:38 am
WORCESTER – Researchers at UMass Medical School last week announced a potential new breakthrough in the treatment of amyotrophic lateral sclerosis. The proposed gene therapy technique, which involves ... […]
- UMass research nearing clinical trials for ALS therapy on October 31, 2018 at 1:50 pm
Researchers at UMass Medical School in Worcester think a new kind of gene therapy may safely treat patients with ALS. A study from professors Christian Mueller and Robert Brown Jr. shows a gene therap... […]
- UMass Medical School study safely delivers RNAi-based gene therapy for ALS in animal model on October 31, 2018 at 11:31 am
WORCESTER, MA -- Promising new research by Christian Mueller, PhD, and Robert H. Brown Jr., DPhil, MD, at the University of Massachusetts Medical School, provides evidence that a therapy using synthet... […]
via Bing News